No Data
No Data
Optimistic Buy Rating for Mediwound: Strong Financials and Strategic Growth Initiatives Highlight Promising Future
H.C. Wainwright Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25
Craig-Hallum Maintains MediWound(MDWD.US) With Buy Rating, Announces Target Price $39
Mediwound (MDWD) Receives a New Rating From Craig-Hallum
Loss-Making MediWound Ltd. (NASDAQ:MDWD) Expected To Breakeven In The Medium-Term
MediWound Analyst Ratings